Additionally, the emergence of next-generation PPAR modulators [6], such as the selective PPARα modulator, pemafibrate, and dual- and pan-PPAR agonists such as saroglitazar, elafibranor, lanifibranor, and chiglitazar, brings about new prospects to PPAR cancer research. Here, PPARA is linked to cancer.